Ovelle Limited, established in 1934, is a privately held pharmaceutical company based in Dundalk, Ireland. The company specializes in the development and manufacturing of dermatological skincare products, combining a rich heritage in dermatology with modern scientific advancements to offer a comprehensive range of licensed and over-the-counter (OTC) skin healthcare solutions.
Key Strategic Focus
Ovelle's strategic focus centers on producing therapeutic skincare products that address various skin conditions. Operating within a fully integrated research and Good Manufacturing Practice (GMP) facility, the company emphasizes safety-tested formulations designed to promote healthy skin and effectively treat skin conditions. Ovelle's product portfolio includes dermatological creams, ointments, and washes formulated by specialists to hydrate, replenish, and smooth the skin. The company serves a diverse market, including Europe, North America, and Asia.
Financials and Funding
As of the latest available financial report dated January 1, 2022, Ovelle Limited reported a turnover of €10.4 million, reflecting a 19.23% increase from the previous year. The company's gross profit stood at €8.1 million, marking a 69.31% increase. The profit after tax was €603,846, and the company maintained a working capital of €3.6 million. The adjusted EBITDA for the same period was €941,356, representing a 78.83% increase compared to the previous year. The company employs approximately 79 individuals, with a 1% increase in staff compared to the previous year.
Technological Platform and Innovation
Ovelle operates a fully integrated research and GMP manufacturing facility in Ireland, enabling the company to maintain stringent quality control and foster innovation in dermatological skincare. The in-house research and development team focuses on creating an industry-leading pipeline of new dermatological products and innovations. The company's scientists combine advances in skincare with a long-standing tradition in dermatology to develop a wide range of licensed and OTC skin healthcare products.
Leadership Team
The leadership team at Ovelle Limited comprises experienced professionals dedicated to advancing the company's mission in dermatological skincare. Key executives include:
- Joanna Gardiner: Serving as a director, Joanna brings extensive experience in the pharmaceutical industry, contributing to the company's strategic direction and growth.
- John Gardiner: As a director, John plays a pivotal role in overseeing the company's operations and ensuring adherence to industry standards.
- Patrick Gardiner: Patrick's role as a director involves guiding the company's financial strategies and corporate governance.
- John Fergus McArdle: Serving as a director, John Fergus contributes to the company's operational management and strategic planning.
- Anthony Patrick Nordon: As a director, Anthony Patrick provides insights into market expansion and business development.
- Michael Power: Michael's role as a director includes overseeing compliance and regulatory affairs.
- Patrick Rigney: Serving as a director, Patrick focuses on innovation and product development strategies.
Competitor Profile
Ovelle Limited operates in the competitive pharmaceutical and dermatological skincare industry. Key competitors include:
- GlaxoSmithKline (Ireland) Limited: A major player in the pharmaceutical industry, offering a wide range of healthcare products.
- AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company: Known for its innovative medicines in various therapeutic areas.
- Covetrus IE Limited: Specializes in animal health products and services.
- CCL Label Ireland Limited: Provides packaging solutions for the pharmaceutical and consumer goods industries.
- Servier Laboratories (Ireland) Limited: Focuses on research and development of therapeutic solutions.
The dermatological skincare market is characterized by continuous innovation, with companies striving to develop effective and safe products to meet consumer needs. Ovelle's commitment to quality and its integrated manufacturing capabilities position it competitively within this dynamic landscape.
Strategic Collaborations and Partnerships
Ovelle Limited has established a growing portfolio of multinational companies and high-profile retailers as strategic partners. These collaborations enhance the company's market reach and innovation capacity, allowing it to offer a diverse range of dermatological products to a global customer base.
Operational Insights
Ovelle's fully integrated research and manufacturing facility in Ireland provides a distinct competitive advantage, enabling the company to maintain stringent quality control and foster innovation. The company's emphasis on safety-tested formulations and its commitment to addressing various skin conditions position it favorably in the dermatological skincare market.
Strategic Opportunities and Future Directions
Looking ahead, Ovelle Limited aims to expand its product portfolio and strengthen its presence in existing and new markets. The company's focus on research and development, coupled with its integrated manufacturing capabilities, positions it to capitalize on emerging trends in dermatological skincare and meet the evolving needs of consumers worldwide.
Contact Information
- Website: www.ovelle.ie
- Social Media: LinkedIn
- Headquarters: Dundalk, County Louth, Ireland
